Core Insights - Werewolf Therapeutics presented preclinical data at the 2025 Society for Immunotherapy of Cancer's Annual Meeting, showcasing advancements in their INDUCER™ T Cell Engager Platform designed to enhance safety and efficacy in cancer treatment [1][2][3] Group 1: Technology and Innovation - The proprietary PREDATOR platform utilizes clinically validated protease-cleavable linkers for tumor-selective activation, leading to the development of three clinical-stage INDUKINE candidates [2][6] - The INDUCER molecules employ a novel masking strategy that prevents systemic T cell activation and cytokine release, activating only in the presence of human tumor tissue [5][6] - A sequential dosing regimen of mWTX-330 (IL-12) followed by WTX-124 (IL-2) demonstrated superior tumor-killing ability compared to either drug alone, indicating a complementary immune mechanism [5][6] Group 2: Clinical Data and Findings - Real-time pharmacokinetic data confirmed WTX-124's selective activation in tumors, with minimal active cytokine released in the plasma, validating the prodrug design [5][6] - The sequential administration strategy enhances antitumor activity while improving tolerability, suggesting a potent and translatable therapeutic strategy [5][6] - The localized release of IL-2 in the tumor environment increased the infiltration of NK and CD8+ T cells, as well as the production of effector cytokines like IFNg [5][6] Group 3: Company Overview - Werewolf Therapeutics is focused on developing conditionally activated therapeutics to stimulate the immune system for cancer treatment, with advanced candidates WTX-124 and WTX-330 targeting solid tumors [6]

Core Insights - Werewolf Therapeutics presented preclinical data at the 2025 Society for Immunotherapy of Cancer's Annual Meeting, showcasing advancements in their INDUCER™ T Cell Engager Platform designed to enhance safety and efficacy in cancer treatment [1][2][3] Group 1: Technology and Platform - The proprietary PREDATOR platform utilizes clinically validated protease-cleavable linkers for tumor-selective activation, leading to the development of three clinical-stage INDUKINE candidates [2][6] - The INDUCER molecules employ a novel masking strategy that prevents systemic T cell activation and cytokine release, activating only in the presence of human tumor tissue [5][6] Group 2: Preclinical Findings - A sequential dosing regimen of mWTX-330 (IL-12) followed by WTX-124 (IL-2) demonstrated superior tumor-killing ability in preclinical models, suggesting enhanced immune response and tolerability [5][6] - Real-time pharmacokinetic data confirmed that WTX-124 selectively activates within tumors, with minimal active cytokine released into the plasma, validating the prodrug design [5][6] Group 3: Company Overview - Werewolf Therapeutics focuses on developing therapeutics that stimulate the immune system for cancer and immune-mediated conditions, with advanced candidates WTX-124 and WTX-330 targeting solid tumors [6]